OC
FPRX

Oakworth Capital’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Oakworth Capital’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-207
Closed -$5K – 660
2017
Q4 		$5K Hold
207
– – ﹤0.01% 522
2017
Q3 		$7K Hold
207
– – ﹤0.01% 508
2017
Q2 		$6K Hold
207
– – ﹤0.01% 516
2017
Q1 		$7K Hold
207
– – ﹤0.01% 507
2016
Q4 		$12K Hold
207
– – ﹤0.01% 438
2016
Q3 		$11K Buy
+207
New +$9.88K ﹤0.01% 433

Other funds holding FPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Oakworth Capital's FPRX Position: Q1 2018 in Review

Oakworth Capital sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 207 shares — an estimated $5K sold.

Oakworth Capital first reported a position in FPRX in Q3 2016 and held it in 6 quarters. The position peaked at $12K in Q4 2016. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

  • Oakworth Capital reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • Oakworth Capital sold 207 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $5K.
  • Oakworth Capital first reported a position in Five Prime Therapeutics, Inc. in Q3 2016 and held it in 6 quarters.
  • Oakworth Capital's Five Prime Therapeutics, Inc. position peaked at $12K in Q4 2016.
  • 128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Oakworth Capital's 13F filing for Q1 2018, filed 9 May 2018.